Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

23.63 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Why Dyne Therapeutics Stock Crushed the Market on Monday
Biotechs like it are clearly valuable to strategic acquirers. 
Via The Motley Fool
Which stocks are moving on Monday?
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Keep an eye on the top gainers and losers in Monday's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis
Via Stocktwits
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ... 
Via Benzinga
Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Looking Into Dyne Therapeutics's Recent Short Interest
 
Via Benzinga
Peering Into Dyne Therapeutics's Recent Short Interest
 
Via Benzinga
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss
 
Via Benzinga
Dyne Reports Wider Loss in Fiscal Q2
Via The Motley Fool
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
These stocks are moving in today's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Dyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug Trial
The updated study will enroll 60 participants and track additional measures like muscle strength, mobility, and patient-reported outcomes. 
Via Stocktwits
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Which stocks are moving on Tuesday?
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
Why Is Dyne Therapeutics Stock Trading Lower On Tuesday?
Dyne updates DYNE-101 trial timeline, reports strong 12-month data, and receives FDA Breakthrough Therapy status for treating DM1. 
Via Benzinga
Get insights into the top gainers and losers of Tuesday's pre-market session.
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path
JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates. 
Via Benzinga
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?
Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated Approval by 2026. 
Via Benzinga
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.